Treatment for high-risk patients with early-stage non-small-cell lung cancer

Affiliations

¹ VU University Medical Center, Amsterdam, the Netherlands; London University of Western Ontario, London, Canada; and Harvard School of Public Health, Harvard University, Boston, MA Dr.alexlouie@gmail.com.
² VU University Medical Center, Amsterdam, the Netherlands.

Comment

Alexander V Louie et al. J Clin Oncol. 2015.

. 2015 Feb 1;33(4):377.

doi: 10.1200/JCO.2014.58.1314. Epub 2014 Dec 22.

¹ VU University Medical Center, Amsterdam, the Netherlands; London University of Western Ontario, London, Canada; and Harvard School of Public Health, Harvard University, Boston, MA Dr.alexlouie@gmail.com.
² VU University Medical Center, Amsterdam, the Netherlands.

No abstract available

Comment in

Reply to A.V. Louie et al.
Fernando HC. Fernando HC. J Clin Oncol. 2015 Feb 1;33(4):378. doi: 10.1200/JCO.2014.59.3277. Epub 2014 Dec 22. J Clin Oncol. 2015. PMID: 25534377 No abstract available.

Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer.
Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, Hillman SL, Heron DE, Meyers BF, DiPetrillo TA, Jones DR, Starnes SL, Tan AD, Daly BD, Putnam JB Jr. Fernando HC, et al. J Clin Oncol. 2014 Aug 10;32(23):2456-62. doi: 10.1200/JCO.2013.53.4115. Epub 2014 Jun 30. J Clin Oncol. 2014. PMID: 24982457 Free PMC article. Clinical Trial.